Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Mde Mdd Calculation topic
No spam. Unsubscribe anytime.
FDA panel: no blanket pill‑count cutoff; MDE/MDD depends on population and product
Summary
FDA speakers said there is no single pill‑count cutoff for maximum daily exposure calculations and that sponsors should seek product‑specific input; for mg/kg labeling, a 60‑kg assumption may be used for typical populations but patient population characteristics should guide the choice.
Industry participants asked several questions about how to calculate maximum daily exposure (MDE) and maximum daily dose (MDD) for product submissions, and agency staff emphasized that context matters.
Dr. Mueller told the panel there is no fixed numerical cutoff such as a 20‑pill rule: "So we don't actually have a cutoff of 20 pills per day, or 20 dose units." She recommended that sponsors submit controlled correspondence for case‑specific guidance rather than rely on a single default value.
On labeling that reports dose as milligrams per kilogram per day, Dr. Mueller said sponsors should select a kilogram value based on the expected patient population. "Then the kilogram could be the 60 kilogram could be used," she said for standard‑weight populations. If the target population is expected to be substantially outside the typical weight range (for example, a product for a disease associated with obesity or low body weight), the agency advised choosing a value appropriate to that clinical disease state.
For products administered at longer intervals (weekly or monthly), Dr. Mueller said FDA evaluates the amount administered on the day of dosing as a worst‑case: a transdermal system applied once is considered that day's dose even if it remains in place for several days. The panel repeatedly urged sponsors to request specific input when assumptions about population or dosing intervals could materially change exposure calculations.
